Allogene’s ALLO-316 Achieves 31% Response Rate in Advanced Renal Cell Carcinoma
ALLO-316 achieves 31% response rate in advanced renal cell carcinoma patients previously resistant to checkpoint inhibitors and tyrosine kinase...
![Stack of documents clipped with a black binder clip on a wooden desk, with a pen and glasses nearby in sunlight] ,](https://www.clinicaltrialvanguard.com/wp-content/uploads/2026/07/your-recruitment-plan-is-failing-before-screening-even-start-750x575.png)
Your Recruitment Plan Is Failing Before Screening Even Starts
59% of sites report recruitment blocked by process inefficiencies—the bottleneck isn't patient supply, it's the workflow that never gets...
SCI-110’s Phase IIb in Tourette Syndrome: What Hannover Tells Us About Cannabinoid Trial Design in CNS
NeuroThera Labs activates Hannover Medical School for SCI-110 Phase IIb in adult Tourette Syndrome, building on a 21% tic...
When the Site Is Also the Sponsor: Princess Máxima’s Rinke Riezebos on Data Standardization, Protocol Design, and Why Sponsors Should Listen to Their Sites
Princess Máxima Center for Pediatric Oncology is both sponsor and site, and that dual vantage point gives Rinke Riezebos...
59% of Clinical Trial Sites Losing Eligible Patients to Process Inefficiencies
59% of clinical trial sites lose eligible patients due to process inefficiencies rather than patient scarcity, revealing a throughput...
ORIC Initiates Himalayas-1 Phase 3 Trial of Rinzimetostat for mCRPC
ORIC initiates Himalayas-1 Phase 3 trial of rinzimetostat plus darolutamide in 600 mCRPC patients previously treated with abiraterone.
Hemab’s Sutacimig Cuts Bleeds 84% in Phase 2 Glanzmann Thrombasthenia Study
Hemab's sutacimig cut treated bleeds 84% in Phase 2 Glanzmann Thrombasthenia study, advancing weekly subcutaneous prophylaxis toward Phase 3...
Biogen’s diranersen shows 26% slowing of cognitive decline in early Alzheimer’s
Biogen's diranersen slows cognitive decline in early Alzheimer's by 26% in Phase 2 trial, matching approved amyloid therapies with...
Kelun-Biotech’s sac-TMT Plus Pembrolizumab Hits Primary Endpoint in PD-L1-Negative NSCLC
Kelun-Biotech's sac-TMT Plus Pembrolizumab hits primary endpoint in PD-L1-negative NSCLC, showing statistically significant progression-free survival improvemen
FDA Grants Priority Review to Roche’s Gazyva for Primary Membranous Nephropathy
FDA grants priority review to Roche's Gazyva for primary membranous nephropathy based on phase III trial showing 36.9% complete...